|
gptkbp:instanceOf
|
gptkb:biotechnology
gptkb:drug
|
|
gptkbp:administeredBy
|
patients with transfusion-dependent anemia
|
|
gptkbp:approvalYear
|
2019
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
B03XA06
|
|
gptkbp:brand
|
gptkb:Reblozyl
|
|
gptkbp:CASNumber
|
1334230-33-6
|
|
gptkbp:contraindication
|
pregnancy
|
|
gptkbp:developer
|
gptkb:Acceleron_Pharma
gptkb:Bristol_Myers_Squibb
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
luspatercept
|
|
gptkbp:KEGGID
|
D11041
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:protein
|
|
gptkbp:mechanismOfAction
|
erythroid maturation agent
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:PubChem_CID
|
DB15016
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
diarrhea
fatigue
headache
hypertension
bone pain
|
|
gptkbp:target
|
transforming growth factor-beta (TGF-β) superfamily ligands
|
|
gptkbp:UNII
|
6Y7T8XW3A8
|
|
gptkbp:usedFor
|
beta thalassemia
myelodysplastic syndromes
treatment of anemia
|
|
gptkbp:bfsParent
|
gptkb:Acceleron_Pharma
|
|
gptkbp:bfsLayer
|
5
|